Market Place
Sourcing Support
Galectin Therapeutics Acceptance Of Three Abstracts For AASLD 2024
15 Oct 2024 //
GLOBENEWSWIRE
Galectin to Participates In HC Wainwright MASH Conference
30 Sep 2024 //
GLOBENEWSWIRE
Galectin Therapeutics to Present at H.C. Wainwright Global Conference
03 Sep 2024 //
GLOBENEWSWIRE
Galectin Therapeutics Reports Q2 2024 Results And Business Update
13 Aug 2024 //
GLOBENEWSWIRE
Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer
01 Aug 2024 //
GLOBENEWSWIRE
Galectin: Presenting At EASL 2024 Congress
04 Jun 2024 //
GLOBENEWSWIRE
Galectin Therapeutics Reports Q1 2024 Financials, Business Update
15 May 2024 //
GLOBENEWSWIRE
Galectin Therapeutics To Participate In H.C. Wainwright BioConnect Conference
13 May 2024 //
GLOBENEWSWIRE
Galectin Therapeutics Reports NAVIGATE Study Outcome
09 Apr 2024 //
GLOBENEWSWIRE
Galectin Therapeutics Reports 2023 Financial Results
29 Mar 2024 //
GLOBENEWSWIRE
Galectin Therapeutics Expands Clinical Team
12 Mar 2024 //
GLOBENEWSWIRE
Galectin Reports Financial Results for the Quarter Ended September 30, 2023
13 Nov 2023 //
GLOBENEWSWIRE
UPDATE “ Galectin Therapeutics Reports Financial Results for the Quarter Ended
13 Nov 2023 //
GLOBENEWSWIRE
Galectin Therapeutics to Share Five Scientific Presentations
03 Nov 2023 //
GLOBENEWSWIRE
Galectin to Participate in H.C. Wainwright 7th Annual NASH Investor Conference
23 Oct 2023 //
GLOBENEWSWIRE
Galectin Announces Nomination of Dr. Benjamin S. Carson to Board of Directors
12 Oct 2023 //
GLOBENEWSWIRE
Galectin Therapeutics Reports the Positive Outcome of Data for NAVIGATE
03 Oct 2023 //
GLOBENEWSWIRE
Galectin to Present Update on its Belapectin Liver Cirrhosis Program
26 Sep 2023 //
GLOBENEWSWIRE
Galectin to Participate in the H.C. Wainwright 25th Annual Investment Conference
11 Sep 2023 //
GLOBENEWSWIRE
Galectin Therapeutics to Present Data on Liver Cirrhosis
07 Sep 2023 //
GLOBENEWSWIRE
Galectin Therapeutics Reports Financial Results for the Quarter
14 Aug 2023 //
GLOBENEWSWIRE
Galectin Therapeutics Reports FYR for the Quarter Ended March 31, 2023
15 May 2023 //
GLOBENEWSWIRE
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect
27 Apr 2023 //
GLOBENEWSWIRE
Galectin Reports 2022 Financial Results and Provides Business Update
30 Mar 2023 //
GLOBENEWSWIRE
Galectin Reports the Outcome of the Third Data Monitoring Meeting for NAVIGATE
16 Mar 2023 //
GLOBENEWSWIRE
Galectin Therapeutics Provides Final Randomization Status of NAVIGATE
02 Mar 2023 //
GLOBENEWSWIRE
Galectin contribution to improve histology interpretation of cirrhotic liver biopsies
24 Jan 2023 //
GLOBENEWSWIRE
Galectin Therapeutics Announces the End of Enrollment of NAVIGATE
05 Jan 2023 //
GLOBENEWSWIRE
Galectin Therapeutics to Webcast Corporate Update on December 1, 2022
29 Nov 2022 //
GLOBENEWSWIRE
Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit
28 Nov 2022 //
GLOBENEWSWIRE
Galectin Therapeutics Reports Financial Results for Quarter Ended Sep 30, 2022
14 Nov 2022 //
GLOBENEWSWIRE
Galectin to Share Five Scientific Presentations at The Liver Meeting™ 2022
01 Nov 2022 //
GLOBENEWSWIRE
Galectin Therapeutics to Present in Upcoming Conferences
14 Oct 2022 //
GLOBENEWSWIRE
Galectin Receives FDA Approval to Proceed with Combination Immunotherapy
12 Oct 2022 //
GLOBENEWSWIRE
Galectin Reports the Positive Outcome of the Second Data & Safety Monitoring
06 Oct 2022 //
BENZINGA
Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual GHC
08 Sep 2022 //
GLOBENEWSWIRE
Galectin Reports Financial Results for the Quarter Ended June 30, 2022
15 Aug 2022 //
GLOBENEWSWIRE
Galectin Therapeutics Announces $60M Credit Line
26 Jul 2022 //
GLOBENEWSWIRE
Galectin Tx to Present in H.C. Wainwright and 5th Global NASH Congress
23 May 2022 //
GLOBENEWSWIRE
Galectin Tx Reports Financial Results for the Quarter Ended March 31, 2022
16 May 2022 //
GLOBENEWSWIRE
Galectin Tx Reports Positive Outcome of Safety Monitoring Board of Belapectin
14 Apr 2022 //
GLOBENEWSWIRE
Galectin Therapeutics Reports 2021 Financial Results
31 Mar 2022 //
GLOBENEWSWIRE
Galectin to Present 6 Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD
05 Nov 2021 //
GLOBENEWSWIRE
Galectin Pharma to Present Six Scientific Abstracts at The Liver Meeting™
27 Oct 2021 //
GLOBENEWSWIRE
Galectin Therapeutics does Strategic Hires to Advance Programs in NASH & cancer
30 Aug 2021 //
GLOBENEWSWIRE
Galectin Therapeutics Reports Financial Results for the Quarter
16 Aug 2021 //
GLOBENEWSWIRE
Galectin Announces Results from Phase 1b Clinical Trial Extension of Belapectin
09 Jul 2021 //
GLOBENEWSWIRE
Galectin Therapeutics to Present at 4th Global NASH Congress
27 Apr 2021 //
GLOBENEWSWIRE
Galectin Therapeutics Inc. Recaps Results of Annual Meeting of Stockholders
04 Dec 2020 //
GLOBENEWSWIRE
Galectin Provides Business Update And Reports Financial Results
09 Nov 2020 //
GLOBENEWSWIRE
Galectin Therapeutics Announces Commencement Ph2b/3 Trial of Belapectin
30 Jun 2020 //
GLOBENEWSWIRE
Galectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b/3 NASH-RX
30 Apr 2020 //
GLOBENEWSWIRE
